Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002

Bibliography

• STEWART S, MACINTYRE K, HOLE DJ, CAPEWELL S, MCMURRAY JJ: More 'malignant than cancer? Five-year survival following a first admission for heart failure. Ear: Heart Fail. (2001) 3:315–322.
   PubMed Web of Science ®Google Scholar
• KJAER A, HESSE B: Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin. Physiol (2001) 21:661–672.
   PubMedGoogle Scholar
• SALLACH JA, GOLDSTEIN S: Use of 13-blockers in congestive heart failure. Ann. Med. (2003) 35:259–266.
   PubMed Web of Science ®Google Scholar
• STERGREN J, MCMURRAY JJ: Angiotensin receptor blockers in heart failure. I Renin Angiotensin Aldosterone Syst. (2003) 4:171–175.
   PubMedGoogle Scholar
• RICH S, MCLAUGHLIN VV: Endothelin receptor blockers in cardiovascular disease. Circulation (2003) 108:2184–2190.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G: Valsartan Heart failure trial investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. I Med. (2001) 345:1667–1675.
   Google Scholar
• MURRAY JJ, OSTERGREN J, SWEDBERG K et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767–771.
   PubMedGoogle Scholar
• SPIEKER LE, NOLL G, LUSCHER TF:Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am. J. Cardiovasc. Drugs (2001) 1:293–303.
   PubMedGoogle Scholar
• The cardiac insufficiency bisoprolol study II(CIBIS-II): a randomised trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• PACKER M, COATS AJ, FOWLER MB et al. Carvedilol prospective randomised cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl. I Med. (2001) 344:1651–1658.
   Google Scholar
• NO AUTHORS LISTED: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet (1999) 353:2001–2007.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomised controlled trial. Lancet (2003) 362:7–13.
   PubMed Web of Science ®Google Scholar
• B-BLOCKER EVALUATION OF SURVIVAL TRIAL INVESTIGATORS: A trial of the P-blocker bucindolol in patients with advanced chronic heart failure. N Engl. Med. (2001) 344:1659–1667.
   PubMedGoogle Scholar
• COHN JN, PFEFFER MA, ROULEAU J et al.: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur: J. Heart Fail. (2003) 5:659–667.
   PubMed Web of Science ®Google Scholar
• AZZAZY HM, CHRISTENSON RH: B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail. Rev (2003) 8:315–320.
   PubMed Web of Science ®Google Scholar
• DE LEMOS JA, MCGUIRE DK, DRAZNER MH: B-type natriuretic peptide in cardiovascular disease. Lancet (2003) 362:316–322.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.j Card Fail. (1998) 4:37–44.
   PubMedGoogle Scholar
• FENG JA, PERRY G, MORI T, HAYASHI T, OPARIL S, CHEN YF: Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice. Clin. Exp. Pharmacol Physiol (2003) 30:343–349.
   PubMed Web of Science ®Google Scholar
• ROSENKRANZ AC, WOODS RL, DUSTING GJ, RITCHIE RH: Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc. Res. (2003) 57:515–522.
   PubMedGoogle Scholar
• BURNETT JC JR, KAO PC, HU DC et al.: Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 231:1145–1147.
   PubMedGoogle Scholar
• OMLAND T, AAKVAAG A, BONARJEE VV et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation (1996) 93:1963–1969.
   Google Scholar
• PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 106:920–926.
   PubMed Web of Science ®Google Scholar
• MARKS DL, LING N, CONE RD: Role of the central melanocortin system in cachexia. Cancer Res. (2001) 61:1432–1438.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, NIKITIN N, MCGOWAN J: Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure. Expert Rev Cardiovasc. Ther: (2004) 2:9–19.
   PubMedGoogle Scholar
• NIEMINEN MS, AKKILA J, HASENFUSS G et al.: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. JACC (2000) 36:1903–1912.
   Google Scholar
• FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360:196–202.
   PubMed Web of Science ®Google Scholar
• MOISEYEV VS, PODER P, ANDREJEVS N et al: Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomised, placebo-controlled, double-blind study (RUSSLAN). Eur: Heart J. (2002) 23:1422–1432.
   Google Scholar
• ECHT DS, LIEBSON PR, MITCHELL LB et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl. Med. (1991) 324:781–788.
   PubMed Web of Science ®Google Scholar
• DOVAL HC, NUL DR, GRANCELLI HO, PERRONE SV, BORTMAN GR, CURIEL R: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina (GESICA). Lancet (1994) 344:493–498.
   Google Scholar
• SINGH SN, FLETCHER RD, FISHER SG et al: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl. I Med. (1995) 333:77–82.
   Google Scholar
• NACCARELLI GV, WOLBRETTE DL, PATEL HM, LUCK JC: Amiodarone: clinical trials. Curt: Opin. Cardiol (2000) 15:64–72.
   Google Scholar
• HABER HL, LEAVY JA, KESSLER PD,KUKIN ML, GOTTLIEB SS, PACKER M: The erythrocyte sedimentation rate in congestive heart failure. N Engl.' Med. (1991) 324:353–358.
   PubMed Web of Science ®Google Scholar
• RICH MW, BECKHAM V, WITTENBERG C, LEVEN CL, FREEDLAND KE, CARNEY RM: A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl. I Med. (1995) 333:1190–1195.
   PubMed Web of Science ®Google Scholar
• SZACHNIEWICZ J, PETRUK -KOWALCZYK J, MAJDA J et al.: Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. hat. Cardiol (2003) 90:303–308.
   Google Scholar
• KALRA PR, BOLGER AP, FRANCIS DP et al.: Effect of anaemia on exercise tolerance in chronic heart failure in men. Am. J. Cardiol (2003) 91:888–891.
   PubMedGoogle Scholar
• AL-AHMAD A, RAND WM, MANJUNATH G et al.: Reduced kidney function and anaemia as risk factors for mortality in patients with left ventricular dysfunction. .1 Am. Coll. Cardiol (2001) 38:955–962.
   Google Scholar
• HORWICH TB, FONAROW GC, HAMILTON MA, MACLELLAN WR, BORENSTEIN J: Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. I Am. Coll. Cardiol (2002) 39:1780–1786.
   PubMed Web of Science ®Google Scholar
• WINEARLS CG, OLIVER DO, PIPPARD MJ, REID C, DOWNING MR, COTES PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet (1986) 2:1175–1178.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, BLUM M et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anaemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalisations. Am. Coll. Cardiol (2000) 35:1737–1744.
   PubMed Web of Science ®Google Scholar
• MANCINI DM, KATZ SD, LANG CC, LAMANCA J, HUDAIHED A, ANDRONE AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation (2003) 107:294–299.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, BLUM Met al.: Effect of correction of anaemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. hr. Med. Assoc.' (2003) 5:337–339.
   Google Scholar
• SILVERBERG DS, WEXLER D, BLUM M et al.: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Neplmol. Dial. Transplant. (2003) 18:141–146.
   PubMed Web of Science ®Google Scholar
• HENKE M, LASZIG R, RUBE C et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 362:1255–1260.
   PubMed Web of Science ®Google Scholar
• ANKER SD, SHARMA R: The syndrome of cardiac cachexia.Cardiol (2002)85:51–66.
   Google Scholar
• ANKER SD, PONIKOWSKI PP, CLARK AL et al.: Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J. (1999) 20:683–693.
   PubMed Web of Science ®Google Scholar
• ANKER SD, CHUA TP, PONIKOWSKI P et al.: Hormonal changes and catabolic/ anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation (1997) 96:526–534.
   PubMed Web of Science ®Google Scholar
• REN J, SAMSON WK, SOWERS JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. Moll. Cell. Cardiol (1999) 31:2049–2061.
   Google Scholar
• NIEBAUER J, PFLAUM CD, CLARK ALet al.: Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation.' Am. Coll. Cardiol (1998) 32:393–397.
   Google Scholar
• VON LEWINSKI D, VOSS K, HULSMANN S, KOGLER H, PIESKE B. Insulin-like growth factor-1 exerts Ca2+-dependent positive inotropic effects in failing human myocardium. Circ. Res. (2003) 92:169–176.
   Google Scholar
• KINUGAWA S, TSUTSUI H, IDE T et al:Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc. Res. (1999) 43:157–164.
   PubMedGoogle Scholar
• KONTOLEON PE, ANASTASIOU-NANA MI, PAPAPETROU PD et al.: Hormonal profile in patients with congestive heart failure. Int.j Cardiol (2003) 87:179–183.
   PubMed Web of Science ®Google Scholar
• HAMBRECHT R, SCHULZE PC, GIELEN S et al: Reduction of insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Am. Coll. Cardiol (2002) 39:1175–1181.
   PubMed Web of Science ®Google Scholar
• VASAN RS, SULLIVAN LM, D 'AGOSTINO RB et al.: Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann. Intern. Med. (2003) 21(139)642–628.
   Google Scholar
• LAUGHLIN GA, BARRETT -CONNOR E, CRIQUI MH, KRITZ-SILVERSTEIN D: The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the rancho bernardo study. I Clin. Endocrinol (2004) 89:114–1120.
   PubMedGoogle Scholar
• GIOVANNUCCI E: Nutrition, insulin, insulin-like growth factors and cancer. Harm. Metal,. Res. (2003) 35:694–704.
   PubMed Web of Science ®Google Scholar
• SWERDLOW AJ, HIGGINS CD, ADLARD P, PREECE MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet (2002) 360:273–277.
   PubMed Web of Science ®Google Scholar
• FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl. I Med. (1996) 334:809–14.
   PubMed Web of Science ®Google Scholar
• OSTERZIEL KJ, STROHM 0, SCHULERJ et al.: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet (1998) 351:1233–7.
   Google Scholar
• ISGAARD J, BERGH CH, CAIDAHL K, LOMSKY M, HJALMARSON A, BENGTSSON BA: A placebo-controlled study of growth hormone in patients with congestive heart failure. Ear: Heart (1998) 19:1704–11.
   Google Scholar
• ANKER SD, VOLTERRANI M, PFLAUM CD et al.: Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol (2001) 38:443–52.
   PubMed Web of Science ®Google Scholar
• CUNEO RC, WILMSHURST P, LOWY C, MCGAULEY G, SONKSEN PH: Cardiac failure responding to growth hormone. Lancet (1989) 1:838–839.
   PubMed Web of Science ®Google Scholar
• O'DRISCOLL JG, GREEN DJ, IRELAND M, KERR D, LARBALESTIER RI: Treatment of end-stage cardiac failure with growth hormone. Lancet (1997) 349:1068.
   PubMed Web of Science ®Google Scholar
• BOCCHI EA, MOURA LZ, GUIMARAES G, BELLOTTI GV, RAMIRES JF: Beneficial effects of high doses of growth hormone in the optimization of medical treatment in decompensated congestive heart failure. J. Am. Coll. Cardiol (2003) 41 (SupplA):265A.
   Google Scholar
• LEE WL, CHEN JW, TING CT et al: Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology (1999) 140:4831–4840.
   PubMed Web of Science ®Google Scholar
• TORELLA D, ROTA M, NURZYNSKA D et al.: Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res. (2004) 94(4):514–524.
   PubMed Web of Science ®Google Scholar
• TOMODA H. Effect of oxymetholone onleft ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am. J. Cardiol (1999) 83:123-5,A9.
   Google Scholar
• MORIYAMA Y, YASUE H, YOSHIMURA M et al: The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Chu. Endocrinol Metab (2000) 85:1834–1840.
   PubMed Web of Science ®Google Scholar
• SWAN JW, ANKER SD, WALTON C et al.: Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol (1997) 30:527–32.
   PubMed Web of Science ®Google Scholar
• KEMPPAINEN J, TSUCHIDA H, STOLEN K et al.: Insulin signalling and resistance in patients with chronic heart failure. Physiol (2003) 550:305–315.
   Google Scholar
• PATERNOSTRO G, CAMICI PG, LAMMERSTMA AA et al: Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. I Chu. Invest. (1996) 98:2094–2099.
   Google Scholar
• SUSKIN N, MCKELVIE RS, BURNS RJ et al.: Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Ear: Heart J. (2000) 21:1368–1375.
   PubMed Web of Science ®Google Scholar
• DOEHNER W, RAUCHHAUS M, DAVOS CH, SHARMA R, BOLGER A, ANKER SD: Clinical significance of impaired insulin sensitivity in chronic heart failure. Circulation (2000) 102(Suppl):II–719A.
   Google Scholar
• WOODFIELD SL, LUNDERGAN CE REINER JS et al.: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J. Am. Coll. Cardiol (1996) 28:1661–1669.
   Google Scholar
• DANIELSEN R, NORDREHAUG JE, LIEN E, VIK-MO H: Subclinical left ventricular abnormalities in young subjects with long-term Type 1 diabetes mellitus detected by digitized M-mode echocardiography. Am. .1. Cardiol (1987) 60:143–146.
   Google Scholar
• PEREZ JE, MCGILL JB, SANTIAGO JV et al.: Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J. Am. Coll. Cardiol (1992) 19:1154–1162.
   PubMed Web of Science ®Google Scholar
• STONE PH, MULLER JE, HARTWELL T et al.: The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J. Am. Coll. Cardiol (1989) 14:49–57.
   PubMed Web of Science ®Google Scholar
• PETRIE JR, UEDA S, WEBB DJ, ELLIOTT HL, CONNELL JM: Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 93:1331–1333.
   Google Scholar
• INOUE T, MATSUNAGA R, SAKAI Y, YAGUCHI I, TAKAYANAGI K, MOROOKA S: Insulin resistance affects endothelium-dependent acetylcholine-induced coronary artery response. Eur: Heart J. (2000) 21:895–900.
   PubMedGoogle Scholar
• WICK KL, LIU F: A new molecular target of insulin action: regulating the pivotal PDK1. Curr. Drug Targets Immune Endocr: Metabol Disord. (2001) 1:209–221.
   Google Scholar
• CHABONNEL B, LONNQVIST F, JONES NP, ABEL MG, PAT WARDHAN R: Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in Type 2 diabetic patients. Diabetes (1999) 48(Suppl 1):A114.
   Google Scholar
• YUE T, CHEN J, BAO W et al: In vivo myocardial protection from ischemia/ reperfusion injury by the perwdsome proliferator-activated receptor- agonist Rosiglitazone. Circulation (2001) 104:2588–2594.
   PubMed Web of Science ®Google Scholar
• SIDELL RJ, COLE MA, DRAPER NJ, DESROIS M, BUCKINGHAM RE, CLARKE K: Thiazolidinedione treatment normalizes insulin resistance and ischaemic injury in the zucker Fatty rat heart. Diabetes (2002) 51:1110–1117.
   PubMed Web of Science ®Google Scholar
• BERRY CE, HARE JM: Xanthine wddoreductase and cardiovascular disease - molecular mechanisms and pathophysiologic implications. J. Physiol (2003) 555(3):589–606.
   PubMedGoogle Scholar
• HARE JM, JOHNSON RJ: Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine wddase and uric acid in disease pathophysiology. Circulation (2003) 107:1951–1953.
   PubMed Web of Science ®Google Scholar
• EKELUND UE, HARRISON RW, SHOKEK 0 et al.: Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. (1999) 85:437–445.
   Google Scholar
• DE JONG JW, SCHOEMAKER RG, DE JONGE R et al.: Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J. Ma Cell. Cardiol (2000) 32:2083–2089.
   Google Scholar
• CAPPOLA TP, KASS DA, NELSON GS et al.: Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation (2001) 104:2407–2411.
   PubMed Web of Science ®Google Scholar
• PEREZ NG, GAO WD, MARBAN E: Novel myofilament Ca2+-sensitizing property of xanthine wddase inhibitors. Circ. Res. (1998) 83:423–430.
   PubMed Web of Science ®Google Scholar
• KOGLER H, FRASER H, MCCUNE S, ALTSCHULD R, MARBAN E: Disproportionate enhancement of myocardial contractility by the xanthine wddase inhibitor oxypurinol in failing rat myocardium. Cardiovasc. Res. (2003) 59:582–592.
   PubMed Web of Science ®Google Scholar
• DOEHNER W, SCHOENE N, RAUCHHAUS M et al: Effects of xanthine wddase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 105:2619–2624.
   PubMed Web of Science ®Google Scholar
• FARQUHARSON CA, BUTLER R, HILL A, BELCH JJ, STRUTHERS AD: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation (2002) 106:221–226.
   PubMed Web of Science ®Google Scholar
• RAUCHHAUS M, DOEHNER W, FRANCIS DP et al.: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 102: 3060–3067.
   PubMed Web of Science ®Google Scholar
• NIEBAUERJ, VOLK HD, KEMP M et al.: Endotwdn and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 353:1838–1842.
   PubMedGoogle Scholar
• VON HAEHLING S, JANKOWSKA EA, ANKER SD: Tumour necrosis factor-a and the failing heart - pathophysiology and therapeutic implications. Basic Res. Cardiol. (2004) 99:18–28.
   PubMed Web of Science ®Google Scholar
• ANKER SD, PONIKOWSKI PP, CLARK AL et al.: Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart (1999) 20:683–693.
   PubMed Web of Science ®Google Scholar
• MANN DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. (2002) 91:988–998.
   PubMed Web of Science ®Google Scholar
• BOLGER AP, ANKER SD: Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs (2000) 60:1245–1257.
   PubMedGoogle Scholar
• ANKER SD, EGERER KR, VOLK HD, KOX WJ, POOLE-WILSON PA, COATS AJ: Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am.j Cardiol. (1997) 79:1426–1430.
   PubMed Web of Science ®Google Scholar
• NIEBAUERJ, VOLK HD, KEMP M et al.: Endotwdn and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 353:1838–1842.
   PubMedGoogle Scholar
• GENTH-ZOTZ S, VON HAEHLING S, BOLGER AP et al.: Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-a release in whole blood from patients with chronic heart failure. Am. J. Cardiol. (2002) 90:1226–1230.
   PubMed Web of Science ®Google Scholar
• SINISALO J, VANHANEN H, PAJUNEN p, VAPAATALO H, NIEMINEN MS: Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. &J. Clin. Pharmacol. (1999) 47:661–665.
   Google Scholar
• OLAUSSON M, MJORNSTEDT L, WRAMNER L, PERSSON H, KARLBERG I, FRIMAN S: Adjuvant treatment with ursodeoxycholic acid prevents acute rejection in rats receiving heart allografts. Transpl. Int. (1992) 5:(Supp1.1):S539–541.
   Google Scholar
• CHUNG ES, PACKER M, LO KH, FASANMADE AA, WILLERSON JT: Anti-TNF therapy against congestive heart failure investigators. Randomised, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation (2003) 107:3133–3140.
   Google Scholar
• MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure. Results of the randomised etanercept worldwide evaluation (RENEWAL). Circulation (2004) 109:r79–r84.
   Google Scholar
• ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. hat. Cardiol. (2002) 86:123–130.
   Web of Science ®Google Scholar
• ANKER SD: Anti-tumour necrosis factor-a therapy in chronic heart failure - what went wrong? In: Heart Failure Updates. McMurray JJ, Pfeffer MA (Eds) Martin Dunitz, London, UK (2003) 201–213.
   Google Scholar
• VON HAEHLING S, ANKER SD, BASSENGE E: Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev (2003) 8:99–106.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA, SACKS F, BRAUNVVALD E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation (1999) 100:230–235.
   Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 7:687–692.
   PubMed Web of Science ®Google Scholar
• PAHAN K, SHEIKH FG, NAMBOODIRI AM, SINGH I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. (1997) 100:2671–2679.
   PubMed Web of Science ®Google Scholar
• CHEN QM, TU VC: Apoptosis and heart failure: mechanisms and therapeutic implications. Am. I Cardiovasc. Drugs (2002) 2:43–57.
   PubMedGoogle Scholar
• OGATA Y, TAKAHASHI M: Bc1-xL as an antiapoptotic molecule for cardiomyocytes. Drug News Perspect. (2003) 16:446–452.
   PubMedGoogle Scholar
• CHANDRASHEKHAR Y, SEN S, AN WAY R, SHUROS A, ANAND I: Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodelling in rats with myocardial infarction. I Am. Coll Cardiol. (2004) 43:295–301.
   PubMedGoogle Scholar
• VON HARSDORF R: Can cardiomyocytes divide? Heart (2001) 86:481–482.
   PubMed Web of Science ®Google Scholar
• DEL MONTE F, HAJJAR RJ, HARDING SE: Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ. Res. (2001) 88:E66–67.
   PubMed Web of Science ®Google Scholar
• MUSARO A, MCCULLAGH K, PAUL A et al.: Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. (2001) 27:195–200.
   PubMed Web of Science ®Google Scholar
• LARSEN Al, LINDAL S, AUKRUST P, TOFT I, AARSLAND T, DICKSTEIN K: Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. Int. .1. Cardiol (2002) 83:25–32.
   Google Scholar
• MANN DL: Mechanisms and models in heart failure: A combinatorial approach. Circulation (1999) 100:999–1008.
   PubMed Web of Science ®Google Scholar